Functional and molecular differentiation of the dopamine system induced by neonatal denervation

Neuroscience and Biobehavioral Reviews

Volumn 20, Issue 3, 1996, Pages 453-486

  Joyce, Jeffrey N ^a,c   Frohna, Paul A ^a   Neal Beliveau, Bethany S ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b INDIANA UNIVERSITY   (United States)

^c SUN HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

6 Hydroxydopamine (6 OHDA); Basal ganglia; Development; Dopamine receptors; Dopaminergic system; Neonatal 6 OHDA lesion; Ontogeny; Plasticity

Indexed keywords

ANIMAL EXPERIMENT; BEHAVIOR; BRAIN INJURY; CELL DIFFERENTIATION; DENERVATION; DOPAMINERGIC SYSTEM; NERVE CELL PLASTICITY; NONHUMAN; ONTOGENY; PRIORITY JOURNAL; RAT; REVIEW;

EID: 0029815348     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/0149-7634(95)00025-9     Document Type: Article

References (285)

1. Agid Y., Javoy F., Glowinski J. Hyperactivity of remaining dopaminergic neurons after partial destruction of the nigrostriatal dopaminergic system in the rat. Nature. 245:1973;150-151.
2. Albin R.L., Young A.B., Penney J.B. The functional neuroanatomy of the basal ganglia disorders. Trends Neurosci. 12:1989;366-375.
3. Almli C.R., Fisher R.S. Infant rats: Sensorimotor ontogeny and effects of substantia nigra destruction. Brain Res. Bull. 2:1977;425-459.
4. Altar C.A., Marien M.R., Marshall J.F. Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: Implications for behavioral recovery from brain injury. J. Neurochem. 48:1987;390-399.
5. Angulo J.A., Coirini H., Ledoux M., Schumacher M. Regulation by dopaminergic neurotransmission of dopamine D2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat. Mol. Brain Res. 11:1991;161-166.
6. Ariano M.A. Comparison of dopamine binding sites in the rat superior cervical ganglion and caudate nucleus. Brain Res. 421:1987;245-254.
7. Ariano M.A. Striatal D1 dopamine receptor distribution following chemical lesion of the nigrostriatal pathway. Brain Res. 443:1988;20-214.
8. 2 receptor sites in reserpine-pretreated but not in normal rats. Eur. J. Pharmacol. 113:1985;79-88.
9. Arnt J. Hyperactivity induced by stimulation of separate D1 and D2 receptors in rats with bilateral 6-OHDA lesions. Life Sci. 37:1985;717-723.
10. 2 antagonists of circling behaviour induced by dopamine agonists in rats with unilateral 6-hydroxydopamine lesions. Eur. J. Pharmacol. 102:1984;349-355.
11. Arnt J., Hyttle J., Perregaard J. Dopamine D-1 receptor agonists combined with a selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Rue. J. Pharmacol. 133:1987;137-145.
12. Baez L.A., Ahlskog J.E., Randall P.K. Body weight and regulatory deficits following unilateral nigrostriatal lesions. Brain Res. 132:1977;467-476.
13. Barone P., Tucci I., Parashos S.A., Chase T.N. D-1 dopamine receptor changes after striatal quinolinic acid lesion. Eur. J. Pharmacol. 138:1987;141-145.
14. Beckstead R.M. The thalamostriatal projection in the cat. J. Comp. Neurol. 233:1984;313-346.
15. Bekenstein J.W., Wooten G.F. Hemicholinium-3 binding sites in rat brain: A quantitative autoradiographic study. Brain Res. 481:1989;97-105.
16. Beresford I.J.M., Davenport A.P., Sirmathsinghi D.J., Hall M.D., Hill R.G., Hughes J. Experimental hemiparkinsonism in the rat following chronic unilateral infusion of MPP+ into the nigrostriatal dopamine pathway. II. Differential localization of dopamine and cholecystokinin receptors Neuroscience. 27:1988;129-143.
17. Berger T.W., Kaul S., Stricker E.M., Zigmond M.J. Hyperinnervation of the striatum by dorsal raphe afferents after dopamine-depleting brain lesions in neonatal rats. Brain Res. 336:1985;354-358.
18. Blanchard V., Chritin M., Vyas S., Savasta M., Feuerstein C., Agid Y., Javoy-Agid F., Raisman-Vozari R. Long-term induction of tyrosine hydroxylase expression: Compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain. J. Neurochem. 64:1995;1669-1679.
19. Blunt D.B., Jenner P., Marsden C.D. Autoradiographic study of striatal D1 and D2 dopamine receptors in 6-OHDA-lesioned rats receiving foetal ventral mesencephalic grafts and chronic treatment with L-dopa and carbidopa. Brain Res. 582:1992;299-311.
20. Boyson S.J., Mcgonigle P., Molinoff P.B. Quantitative autoradiographic localization of the D1 and D2 subtypes of dopamine receptors in rat brain. J. Neurosci. 6:1986;3177-3188.
21. Braun A., Chase T.N. Obligatory D1-D2 receptor coactivation and the generation of dopamine agonist related behaviors. Eur. J. Pharmacol. 131:1986;301-306.
22. Breese G.R., Baumeister A.A., McCown T.J., Emerick S.G., Frye G.D., Crotty K., Mueller R.A. Behavioral differences between neonatal and adult 6-hydroxydopamine-treated rats to dopamine agonists: Relevance to neurological symptoms in clinical syndromes with reduced brain dopamine. J. Pharmacol. Exp. Ther. 231:1984;343-354.
23. Breese G.R., Baumeister A.A., McCown T.J., Emerick S.G., Frye G.R., Mueller R.A. Neonatal-6-hydroxydopamine treatment: Model of susceptibility for self-mutiliation in the Lesch-Nyhan syndrome. Pharmacol. Biochem. Behav. 21:1984;459-461.
24. Breese G.R., Baumeister A., Napier T.C., Frye G.D., Mueller R.A. Evidence that D-1 dopamine receptors contribute to the supersensitive behavioral responses induced by L-dihydroxyphenylalanine in rats treated neonatally with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 235:1985;287-295.
25. 2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther. 240:1987;167-191.
26. Breese G.R., Mueller R.A. SCH23390 antagonism of a D-2 agonist depends upon catecholaminergic neurons. Eur. J. Pharmacol. 113:1985;109-114.
27. Breese G.R., Napier T.C., Mueller R.A. Dopamine agonist-induced locomotor activity in rats treated with 6-hydroxydopamine at differing ages: Functional supersensitivity of D-1 dopamine receptors in neonatally-lesioned rats. J. Pharmacol. Exp. Ther. 234:1985;447-455.
28. Brené S., Lindefors N., Herrera-Marschitz M., Persson H. Expression of dopamine D2 receptor and choline acetyltransferase mRNA in the dopamine deafferented rat caudateputamen. Exp. Brain Res. 83:1990;96-104.
29. Brené S., Lindefors N., Persson H. Midbrain dopamine neurons regulate preprotachykinin-A mRNA expression in the rat forebrain during development. Mol. Brain Res. 14:1992;13-19.
30. Broaddus W.C., Bennett J.P. Jr. Postnatal development of striatal dopamine function. I. An examination of D1 and D2 receptors, adenylate cyclase regulation and presynaptic dopamine markers Dev. Brain Res. 52:1990;265-271.
31. Broaddus W.C., Bennett J.P. Jr. Postnatal development of striatal dopamine function. II. Effects of neonatal 6-hydroxydopamine treatments on D1 and D2 receptors, adenylate cyclase activity and presynaptic dopamine function Dev. Brain Res. 52:1990;273-277.
32. 2, and spirodecanone binding sites in rat forebrain. J. Neurochem. 40:1983;1227-1236.
33. Bruno J.P., Jackson D., Zigmond M.J., Stricker E.M. Effect of dopamine-depleting lesions in rat pups: Role of striatal serotonergic neurons in behavior. Behav. Neurosci. 101:1987;806-811.
34. Bruno J.P., Snyder A.M., Stricker E.M. Effect of dopamine-depleting brain lesions on suckling and weaning in rats. Behav. Neurosci. 98:1984;156-161.
35. Bruno J.P., Stricker E.M., Zigmond M.J. Rats given dopamine-depleting brain lesions as neonates are subsensitive to dopaminergic antagonists as adults. Behav. Neurosci. 99:1985;771-775.
36. Bruno J.P., Zigmond M.J., Stricker E.M. Rats given dopamine-depleting brain lesions as neonates do not respond to acute homeostatic imbalances as adults. Behav. Neurosci. 100:1986;125-128.
37. Burt D.R., Creese I., Snyder S.H. Antischizophrenic drugs: Chronic treatment elevates dopamine receptor binding in brain. Science. 196:1977;326-328.
38. Butcher L.L., Hodge G.K. Postnatal development of acetylcholinesterase in the caudate-putamen nucleus and substantia nigra of rats. Brain Res. 106:1976;223-240.
39. Byrnes E.M., Abrams D., Bruno J.P. Coactivation of D1- and D2-like receptors is unnecessary for stimulated motor behavior in rats depleted of dopamine during development. Behav. Brain Res. 61:1994;205-214.
40. Byrnes E.M., Bruno J.P. Development of uncoupling between D1- and D2-mediated motor behavior in rats depleted of dopamine as neonates. Dev. Psychobiol. 27:1994;409-424.
41. 1 receptor distribution. Dev. Brain Res. 58:1991;111-122.
42. 2 receptors in the regulation of glutamic acid decarboxylase messenger RNA in the striatum of the rat. Eur. J. Neurosci. 4:1992;438-447.
43. 2 receptor mRNA levels in the rat striatum: Effects of unilateral intrastriatal injections of 6-hydroxydopamine. Mol. Brain Res. 12:1992;59-67.
44. Carder R.K., Jackson D., Morris H.J., Lund R.D., Zigmond M.J. Dopamine released from mesencephalic transplants restores modulation of striatal acetylcholine release after neonatal 6-hydroxydopamine; An in vitro analysis. Exp. Neurol. 105:1989;251-259.
45. Carder R.K., Snyder-Keller A.M., Lund R.D. Amphetamine-and stress-induced turning after nigral transplants in neonatally dopamine-depleted rats. Dev. Brain Res. 33:1987;315-318.
46. Castañeda E., Whishaw I.Q., Lerner L., Robinson T.E. Dopamine depletion in neonatal rats: Effects on behavior and striatal dopamine release assessed by intracerebral microdialysis during adulthood. Brain Res. 508:1990;30-39.
47. 1 dopamine receptor mRNA and mu and delta opioid receptors in rat striatum. Neurochem. Int. 25:1994;355-366.
48. Chen J.F., Weiss B. Ontogenetic expression of D2 dopamine receptor mRNA in rat corpus striatum. Dev. Brain Res. 63:1991;95-104.
49. Christensen A.V., Arnt J., Hyttel J., Svendsen O. Behavioral correlates to the dopamine D-1 and D-2 antagonists. Pol. J. Pharmacol. 36:1984;249-264.
50. Chritin M., Feuerstein C., Savasta M. Time-course of changes in striatal levels of DA uptake sites, DA D2 receptor and preproenkephalin mRNAs after nigrostriatal dopaminergic denervation in the rat. Mol. Brain Res. 19:1993;318-322.
51. Cimino M., Zoli M., Weiss B. Differential ontogenetic expression and regulation of proenkephalin and preprosomatostatin mRNAs in rat caudate-putamen as studied by in situ hybridization histochemistry. Dev. Brain Res. 60:1991;115-122.
52. Civelli O., Bunzow J.R., Grandy D.K., Zhou Q.-Y., Van Tol H.H.M. Molecular biology of the dopamine receptors. Eur. J. Pharmacol. 207:1991;277-286.
53. Clark D., White F.J. D1 dopamine receptor: The search for a function. Synapse. 1:1987;347-388.
54. Coirini H., Schumacher M., Angulo J.A., McEwen B.S. Increase in striatal dopamine D2 receptor mRNA after lesions of haloperidol treatment. Eur. J. Pharmacol. 186:1990;369-371.
55. Costall B., Naylor R.J. The role of telencephalic dopaminergic systems in the mediation of apomorphine stereotyped behaviour. Eur. J. Pharmacol. 24:1973;8-24.
56. Costall B., Naylor R.J. Extrapyramidal and mesolimbic involvement with the stereotypic activity of D- and L-amphetamine. Eur. J. Pharmacol. 25:1974;121-129.
57. Coulon J.F., Biguet N.F., Delacour J., Mallet J., David J.C. Gene expression of tyrosine hydroxylase in the developing fetal brain. J. Neurochem. 55:1990;1412-1417.
58. s-protein coupling. Eur. J. Pharmacol. 207:1991;271-274.
59. Coyle J.T., Axelrod J. Tyrosine hydroxylase in rat brain: Developmental characteristics. J. Neurochem. 19:1972;1117-1123.
60. Coyle J.T., Campochiaro P. Ontogenesis of dopaminergic-cholinergic interactions in the rat striatum. A neurochemical study. J. Neurochem. 27:1976;673-678.
61. Creese, I.; Burt D.R.; Snyder, S.H. Dopamine receptor binding enhancement accompanies lesion-induced behavioral supersensitivity. Science 197:596-498;1977.
62. Creese I., Iversen S.D. The role of forebrain dopamine systems in amphetamine-induced stereotyped behaviour in the rat. Psychopharmacology. 39:1974;345-357.
63. Creese I., Sibley D.R. Receptor adaptations to centrally acting drugs. Annu. Rev. Pharmacol. Toxicol. 21:1981;357-391.
64. 2 dopamine receptor mRNAs: Ontogenetic and pharmacological studies. Neurochem. Int. 20(Suppl.):1992;45S-48S.
65. Criswell H.E., Breese G.R., Mueller R.A. Priming of D1-dopamine receptor responses: Long-lasting behavioral supersensitivity to D1-dopamine agonist following repeated administration to neonatal 6-OHDA-lesioned rats. J. Neurosci. 9:1989;125-133.
66. 1 dopamine receptors. Neuropsychopharmacology. 7:1992;95-103.
67. Desban M., Kemel M.L., Glowinski J., Gauchy C. Spatial organization of patch and matrix compartments in the rat striatum. Neuroscience. 57:1993;661-671.
68. Descarries L., Soghomonian J.-J., Garcia S., Doucet G., Bruno J.P. Ultrastructural analysis of the serotonin hyperinnervation in adult rat neostriatum following neonatal dopamine denervation with 6-hydroxydopamine. Brain Res. 569:1992;1-13.
69. Deskin R., Seidler F.J., Whitmore W.L., Slotkin T.A. Development of alpha-noradrenergic and dopaminergic receptor systems depends on maturation of their presynaptic nerve terminals in the rat brain. J. Neurochem. 36:1981;1683-1690.
70. 1 receptors in adult rat striatum after neonatal 6-hydroxydopamine denervation. Brain Res. 536:1990;287-296.
71. Diaz J., Lévesque D., Lammers C.H., Griffon N., Martresk M.-P., Schwartz J.-C., Sokoloff P. Phenotypical characterization of neurons expressing the dopamine D3 receptor in the rat brain. Neuroscience. 65:1995;731-745.
72. Donoghue J.P., Herkenham M. Neostriatal projections from individual cortical fields conform to histochemically distinct striatal compartments in the rat. Brain Res. 365:1986;397-403.
73. Dravid A., Jaton A.L., Enz A., Frei P. Spontaneous recovery from motor asymmetry in adult rats with 6-hydroxydopamine-induced partial lesions of the substantia nigra. Brain Res. 311:1984;361-365.
74. Duncan G.E., Breese G.R., Criswell H.E., Johnson K.B., Schambra U.B., Mueller R.A., Caron M.G., Fremeau R.T. Jr. D1 dopamine receptor binding and mRNA levels are not altered after neonatal 6-hydroxydopamine treatment: Evidence against dopamine-mediated induction of D1 dopamine receptors during postnatal development. J. Neurochem. 61:1993;1255-1262.
75. Duncan G.E., Criswell H.E., McCown T.J., Paul I.A., Mueller R.A., Breese G.R. Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine. J. Pharmacol. Exp. Ther. 243:1987;1027-1033.
76. Dunnett S., Iversen S.D. Regulatory impairments following selective 6-OHDA lesions of the neostriatum. Behav. Brain Res. 4:1982;195-202.
77. Egan M.F., Hurd Y., Hyde T.M., Weinberger D.R., Wyatt R.J., Kleinman J.E. Alterations in mRNA levels of D2 receptors and neuropeptides in striatonigal neurons of rats with neuroleptic-induced dyskinesias. Synapse. 18:1994;178-189.
78. Ehrlich M.E., Rosen N.L., Kurihara T., Shalaby I.A., Greengard P. DARP-32 development in the caudate nucleus is independent of afferent input from the substantia nigra. Dev. Brain Res. 54:1990;257-263.
79. Erinoff L., MacPhail R.C., Heller A., Seiden L.S. Age-dependent effects of 6-hydroxydopamine on locomotor activity in the rat. Brain Res. 164:1979;195-205.
80. Fallon J.H., Moore R.Y. Catecholamine innervation of the basal forebrain. IV. Topography of the dopamine projection to the basal forebrain and neostriatum. J. Comp. Neurol. 180:1978;545-580.
81. Fentress J.C., Stanfield B.B., Cowan W.M. Observations on the development of the striatum in mice and rats. Anat. Embryol. 163:1981;275-298.
82. Fibiger H., Zis A., McGeer E. Feeding and drinking deficits after 6-hydroxydopamine administration in the rat: Similarities to the lateral hypothalamic syndrome. Brain Res. 55:1973;135-148.
83. Fishburn C.S., David C., Carmon S., Fuchs S. The effect of haloperidol on D2 dopamine receptor subtype mRNA levels in the brain. FEBS Lett. 339:1994;63-66.
84. Fishell G., van der Kooy D. Pattern formation in the striatum: Developmental changes in the distribution of striatonigral neurons. J. Neurosci. 7:1987;1969-1978.
85. Foster G.A., Schultzberg M., Hökfelt T., Goldstein M., Hemmings H.C., Ouimet C.C., Walaas S.I., Greengard P. Development of a dopamine- and cyclic adenosine 3′:5′-monophosphate-regulated phosphoprotein (DARPP-32) in the prenatal rat central nervous system, and its relationship to the arrival of presumptive dopaminergic innervation. J. Neurosci. 7:1987;1994-2018.
86. Friede R.L. Histochemical investigation on succinic dehydrogenase in the central nervous system. J. Neurochem. 4:1959;101-110.
87. Friedhoff A.J., Miller J.C. Prenatal psychotropic drug exposure and the development of central dopaminergic and cholinergic neurotransmitter systems. Monogr. Neurol. Sci. 9:1983;91-98.
88. Frohna P.A., Neal-Beliveau B.S., Joyce J.N. Neonatal 6-OHDA lesions upregulate adult expression of tyrosine hydroxylase mRNA. NeuroReport. 4:1993;1095-1098.
89. Frohna P.A., Neal-Beliveau B.S., Joyce J.N. Neonatal 6-OHDA lesions lead to opposing changes in the levels of dopamine receptors and their mRNAs. Neuroscience. 68:1995;505-518.
90. Frohna, P.A.; Neal-Beliveau, B.S.; Joyce, J.N. The phenotypic plasticity of the developing dopaminergic neurons of the SN-VTA complex: Effects of neonatal 6-OHDA lesions. Synapse, In Review.
91. 1 receptor development depends on endogenous dopamine. Dev. Brain Res. 56:1989;137-140.
92. Gerfen C.R. The neostriatal mosaic: Compartmentalization of corticostriatal input and striatonigral output systems. Nature. 311:1984;461-464.
93. Gerfen C.R., Baimbridge K.G., Thibault J. The neostriatal mosaic: III. Biochemical and developmental dissociation of patch-matrix mesostriatal systems. J. Neurosci. 7:1987;3935-3944.
94. 2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432.
95. Gerfen C.R., Herkenham M., Thibault J. The neostriatal mosaic: II. Patch- and matrix-directed mesostriatal dopaminergic and non-dopaminergic systems. J. Neurosci. 7:1987;3915-3934.
96. 1-dopamine receptors and dopamine content in rat striatum. Dev. Brain Res. 35:1987;283-290.
97. Gong L., Kostrzewa R.M., Fuller R.W., Perry K.W. Supersensitization of the oral response to SFK38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J. Pharmacol. Exp. Ther. 261:1992;1000-1007.
98. Gong L., Kostrzewa R.M., Perry K.W., Fuller R.W. Dose-related effects of a neonatal 6-OHDA lesion on SKF38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Dev. Brain Res. 76:1993;233-238.
99. Graham W.C., Crossman A.R., Woodruff G.N. Autoradiographic studies in animal models of hemi-parkinsonism reveal dopamine D2 but not D1 receptor supersensitivity. I. 6-OHDA lesions of ascending mesencephalic dopaminergic pathways in the rat. Brain Res. 514:1990;43-102.
100. Graybiel A.M. Correspondence between the dopamine islands and striosomes of the mammalian striatum. Neuroscience. 13:1984;1157-1187.
101. Graybiel A.M., Liu G.-C., Dunnett S.B. Intrastriatal grafts derived from fetal striatal primordia. I. Phenotype and modular organization. J. Neurosci. 9:1989;3250-3271.
102. Graybiel A.M., Ragsdale C.W., Yoneoka E.S., Elde R.P. An immunohistochemical study of enkephalins and other neuropeptides in the striatum of the cat with evidence that the opiate receptors are arranged to form mosaic patterns in register with the striosomal compartments visible by acetylcholinesterase staining. Neuroscience. 6:1981;377-397.
103. Guennoun R., Bloch B. D2 dopamine receptor gene expression in the rat striatum during ontogeny: An in situ hybridization study. Dev. Brain Res. 60:1991;79-87.
104. 1 and DARPP-32 gene expression in the rat striatum: An in situ hybridization study. Mol. Brain Res. 12:1992;131-139.
105. Guyenet P.G., Agid Y., Javoy F., Beaujouar J.C., Rossier J., Glowinski J. Effects of dopaminergic receptor agonists and antagonists on the activity of the neostriatal cholinergic system. Brain Res. 84:1975;227-244.
106. Hartley E., Seeman P. Development of receptors for dopamine and noradrenaline in rat brain. Eur. J. Pharmacol. 91:1983;391-397.
107. Hattori T., Fibiger H.C. On the use of lesions to localize neurotransmitter receptor sites in the striatum. Brain Res. 238:1982;245-250.
108. Heffner T.G., Seiden L.S. Impaired acquisition of an operant response in young rats depleted of brain dopamine in neonatal life. Psychopharmacology. 79:1983;115-119.
109. Heffner T.G., Zigmond M.J., Stricker E.M. Effects of dopaminergic agonists and antagonists on feeding in intact and 6-hydroxydopamine-treated rats. J. Pharmacol. Exp. Ther. 201:1977;386-399.
110. Hefti F., Melamed E., Wurtman R.J. Partial lesions of the dopaminergic nigrostriatal system in rat brain: Biochemical characterization. Brain Res. 195:1980;123-137.
111. Herkenham M., Moon Edley S., Stuart J. Cell clusters in the nucleus accumbens of the rat, and the mosaic relationship of opiate receptors, acetylcholinesterase and subcortical afferent terminations. Neuroscience. 11:1984;562-593.
112. Herkenham M., Pert C.B. Mosaic distribution of opiate receptors, parafascicular projections and acetylcholinesterase in rat striatum. Nature. 291:1981;415-417.
113. Hollister A.S., Breese G.R., Cooper B.R. Comparison of tyrosine hydroxylase and dopamine-β-hydroxylase inhibition with the effects of various 6-hydroxydopamine treatments on D-amphetamine induced motor activity. Psychopharmacologia. 36:1974;1-16.
114. Hu X.-T., Wachtel S.R., Galloway M.P., White F.J. Lesions of the nigrostriatal dopamine projection increase the inhibitory effects of D1 and D2 dopamine agonists on caudate-putamen neurons and relieve D2 receptors from the necessity of D1 receptor stimulation. J. Neurosci. 10:1990;2318-2329.
115. Jackson D.M., Hashizume M. Bromocriptine-induced locomotor stimulation in mice is modulated by dopamine D-1 receptors. J. Neural Transm. 69:1987;131-145.
116. Jackson D., Stachowiak M.K., Bruno J.P., Zigmond M.J. Inhibition of striatal acetylcholine release by endogenous serotonin. Brain Res. 457:1988;259-266.
117. 2 receptor contributions to ingestive and locomotor behavior are altered after dopamine depletions in neonatal rats. Neurosci. Lett. 118:1990;20-123.
118. Johnson B.J., Bruno J.P. D-1 and D-2 receptor mediation of sensorimotor behavior in rats depleted of dopamine during development. Behav. Brain Res. 47:1992;49-58.
119. 1-dopamine agonists SFK-38393 and A-68930 in neonatal 6-hydroxydopamine-lesioned rats: Behavioral effects and induction of c-fos-like immunoreactivity. J. Pharmacol. Exp. Ther. 262:1992;855-865.
120. Joyce J.N. Multiple dopamine receptors and behavior. Neurosci. Biobehav. Rev. 7:1983;227-256.
121. Joyce J.N. Differential response of striatal dopamine receptor subtypes and cholinergic muscarinic receptors to the loss of dopamine: I. Effects of intranigral or intracerebroventricular 6-hydroxydopamine lesions of the mesostriatal dopamine system. Exp. Neurol. 113:1991;261-276.
122. Joyce J.N. Differential response of striatal dopamine receptor subtypes and cholinergic muscarinic receptors to the loss of dopamine: II. Effects of 6-hydroxydopamine or colchicine microinjections in the VTA or reserpine treatment. Exp. Neurol. 113:1991;277-290.
123. Joyce J.N., Loeschen S., Marshall J.F. Dopamine D-2 receptors in rat caudate-putamen: The lateral to medial gradient does not correspond to dopaminergic innervation. Brain Res. 338:1985;209-218.
124. Joyce J.N., Marshall J.F. Striatal topography of D-2 receptors correlates with indexes of cholinergic neuron localization. Neurosci. Lett. 53:1985;127-131.
125. Joyce J.N., Marshall J.F. Quantitative autoradiography of dopamine D-2 sites in rat caudate-putamen: Evidence for localization to intrinsic neurons and not to neocortical afferents. Neuroscience. 20:1987;773-795.
126. Kajiyama H., Nomura Y. Alterations in dopaminergic and muscarinic cholinergic receptors after subchronic treatment with haloperidol in the developing rat brain. J. Pharm. Dyn. 4:1981;85-90.
127. 2-receptor interaction in turning behaviour induced by dopamine agonists in 6-hydroxydopamine-lesioned rats. Neurosci. Lett. 88:1988;69-74.
128. Kebabian J.W., Calne D.B. Multiple receptors for dopamine. Nature. 277:1979;93-96.
129. Kent J.L., Pert C.B., Herkenham M. Ontogeny of opiate receptors in rat forebrain: Visualization by in vitro autoradiography. Dev. Brain Res. 2:1982;487-504.
130. Koller W.C., Herbster G. D1 and D2 dopamine receptor mechanisms in dopaminergic behaviors. Clin. Neuropharmacol. 11:1988;221-231.
131. Kostrzewa R.M. Dopamine receptor supersensitivity. Neurosci. Biobehav. Rev. 19:1995;1-17.
132. Kostrzewa R.M., Gong L. Supersensitized D1 receptors mediate enhanced oral activity after neonatal 6-OHDA. Pharmacol. Biochem. Behav. 39:1991;677-682.
133. Kostrzewa R.M., Hamdi A. Potentiation of spiperone-induced oral activity in rats after neonatal 6-hydroxydopamine. Pharmacol. Biochem. Behav. 38:1991;215-218.
134. Kostrzewa R.M., Saleh M.I. Impaired ontogeny of striatal dopamine D1 and D2 binding sites after postnatal treatment of rats with SCH-23390 and spiroperidol. Dev. Brain Res. 45:1989;95-101.
135. LaHoste G.J., Marshall J.F. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density. Synapse. 12:1992;14-26.
136. Lanca A.J., Boyd S.R., Kolb B., Van der Kooy D. The development of a patchy organization of the rat striatum. Dev. Brain Res. 27:1986;1-10.
137. Le Moine C., Bloch B. Rat striatal and mesencephalic neurons contain the long isoform of the D2 dopamine receptor mRNA. Mol. Brain Res. 10:1991;283-289.
138. Le Moine C., Normand E., Guitteny A.F., Fouque B., Teoule R., Bloch B. Dopamine receptor gene expression by enkephalin neuron in rat forebrain. Proc. Nat. Acad. Sci. USA. 87:1990;230-234.
139. 2 dopamine receptor gene expression by cholinergic neurons in the rat striatum. Neurosci. Lett. 117:1990;248-252.
140. Lees F.J., Kydd R.R., Wright J.J. Relationship between sensorimotor neglect and the specificity, degree and locus of mesotelencephalic dopaminergic cell loss following 6-OHDA. Psychopharmacology. 85:1985;115-122.
141. 3H]spiperone binding sites in vitro with classical and novel dopamine receptor agonists. Eur. J. Pharmacol. 88:1983;11-26.
142. Leslie C.A., Robertson M.W., Cutler A.J., Bennet J.P. Jr. Postnatal development of D1 dopamine receptors in the medial prefrontal cortex, striatum and nucleus accumbens of normal and neonatal 6-hydroxydopamine treated rats: A quantitative autoradiographic analysis. Dev. Brain Res. 62:1991;109-114.
143. 3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc. Natl Acad. Sci. USA. 89:1992;8155-8159.
144. Lévesque D.L., Martres M.-P., Diaz J., Griffon N., Lammers C.H., Sokoloff P., Schwartz J.-C. A paradoxical regulation of the dopamine D3 receptor expression suggests the involvement of an anterograde factor from dopamine neurons. Proc. Natl Acad. Sci. USA. 92:1995;1719-1723.
145. Lindefors N., Brené S., Herrera-Marschitz M., Persson H. Neuropeptide gene expression brain is differentially regulated by midbrain dopamine neurons. Exp. Brain Res. 89:1990;489-500.
146. Lisovoski F., Haby C., Borrelli E., Schleef C., Revel M.-O., Hindelang C., Zwiller J. Induction of D2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model. Brain Res. Bull. 28:1992;697-701.
147. Loizou L.A. The postnatal ontogeny of monoamine-containing neurones in the central nervous system of the albino rat. Brain Res. 40:1972;395-418.
148. Longoni R., Spina L., Di Chiara G. Permissive role of D-1 receptor stimulation by endogenous dopamine for the expression of postsynaptic D-2-mediated behavioural responses. Yawning in rats. Eur. J. Pharmacol. 134:1987;163-173.
149. Longoni R., Spina L., Di Chiara G. Permissive role of D-1 receptor stimulation for the expression of D-2 mediated behavioral responses: A quantitative phenomenological study in rats. Life Sci. 41:1987;2135-2145.
150. Loopjuijt L.D. Distribution of dopamine D-2 receptors in the rat striatal complex and its comparison with acetylcholinesterase. Brain Res. Bull. 22:1989;805-817.
151. Lowenstein P.R., Slesinger P.A., Singer H.S., Walker L.C., Casanova M.F., Raskin L.S., Price D.L., Coyle J.T. Compartment specific changes in the density of choline and dopamine uptake sites and muscarinic and dopaminergic receptors during the development of the baboon striatum: A quantitative autoradiographic study. J. Comp. Neurol. 288:1989;428-446.
152. Luthman J., Bolioli B., Tsutsumi T., Verhofstad A., Jonsson G. Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in neonatal rat. Brain Res. Bull. 19:1987;269-274.
153. Luthman J., Brodin E., Sundstrom E., Wiehager B. Studies on brain monoamine and neuropeptide systems after neonatal intracerebroventricular 6-hydroxydopamine treatment. Int. J. Dev. Neurosci. 8:1990;549-560.
154. Luthman J., Lindqvist E., Young D., Cowburn R. Neonatal dopamine lesion in the rat results in enhanced adenylate cyclase activity without altering dopamine receptor binding or dopamine- and adenosine 3′:5′-monophosphate-regulated phosphoprotein (DARP-32) immunoreactivity. Exp. Brain Res. 83:1990;85-95.
155. MacKenzie R.G., Stachowiak M., Zigmond M.J. Dopaminergic inhibition of striatal acetylcholine release after 6-hydroxydopamine. Eur. J. Pharmacol. 168:1989;43-52.
156. Mailman R.B., Schultz D.W., Lewis M.H., Staples L., Rollema H., Dehaven D.L. SCH23390: A selective D1 dopamine antagonist with potent D2 behavioral actions. Eur. J. Pharmacol. 101:1984;159-160.
157. Marshall, J.F. Behavioral consequences of neuronal plasticity following injury to nigrostriatal dopaminergic neurons. In: Scheff, S. W., ed. Aging and recovery of function in the central nervous system. New York: Plenum Press; 1984:101-127.
158. Marshall J.F., Berrios N., Sawyer S. Neostriatal dopamine and sensory inattention. J. Comp. Physiol. Psychol. 94:1980;833-846.
159. Marshall J.F., Navarrete R., Joyce J.N. Decreased striatal D1 binding density following mesotelencephalic 6-hydroxydopamine injections: An autoradiographic analysis. Brain Res. 493:1989;247-257.
160. Marshall J.F., Richardson J.S., Teitelbaum P. Nigrostriatal bundle damage and the lateral hypothalamic syndrome. J. Comp. Physiol. Psychol. 87:1974;808-830.
161. Marshall J.F., Ungerstedt U. Supersensitivity to apomorphine following destruction of the ascending dopamine neurons: Quantification using the rotational model. Eur. J. Pharmacol. 41:1977;361-367.
162. Mashurano M., Waddington J.L. Stereotyped behaviour in response to the selective D-2 dopamine receptor agonist RU 24213 is enhanced by pretreatment with the selective D-1 agonist SK&F 38393. Neuropharmacology. 25:1986;947-949.
163. McDougall S.A., Bardo M.T. Ontogenetic changes in dopaminergic pre- and postsynaptic elements in rat brain: Effects of quinpirole and sulpiride. Neuropharmacology. 30:1991;531-534.
164. McGeer E.G., Fibiger H.C., Wickson V. Differential development of caudate enzymes in neonatal rat. Brain Res. 32:1971;433-440.
165. McGonigle P., Boyson S.J., Reuter S., Molinoff P.B. Effects of chronic treatment with selective and nonselective antagonists on the subtypes of dopamine receptors. Synapse. 3:1989;74-82.
166. 1 antagonist. Life Sci. 36:1985;1857-1864.
167. Miller F.E., Heffner T.G., Kotake C., Seiden L.S. Magnitude and duration of hyperactivity following neonatal 6-hydroxydopamine is related to the extent of brain dopamine depletion. Brain Res. 229:1981;123-132.
168. Molloy A.G., O'Boyle K.M., Pugh M.T., Waddington J.L. Locomotor behaviours in response to new selective D-1 and D-2 dopamine receptor agonists, and the influence of selective antagonists. Pharmacol. Biochem. Behav. 25:1986;249-253.
169. Molloy A.G., Waddington J.L. Dopaminergic behaviour stereospecifically promoted by the D-1 agonist R-SK&F 38393 and selectively blocked by the D-1 antagonist SCH 23390. Psychopharmacology. 82:1984;409-410.
170. Moody C.A., Spear L.P. Effects of acute dopamine depletion on responsiveness to D1 and D2 receptor agonists in infant and weanling rat pups. Psychopharmacology. 107:1992;39-49.
171. Moon S.L. Prenatal haloperidol alters striatal dopamine and opiate receptors. Brain Res. 323:1984;109-113.
172. Moon Edley S., Herkenham M. Comparative development of striatal opiate receptors and dopamine revealed by autoradiography and histofluorescence. Brain Res. 305:1984;27-42.
173. Murray A.M., Waddington J.L. Further evidence for two directions of D-1:D-2 dopamine receptor interactions revealed concurrently in distinct elements of typical and atypical behavior: Studies with the new enantioselective D-2 agonist LY 163502. Psychopharmacology. 98:1989;245-259.
174. Murray A.M., Waddington J.L. The induction of grooming and vacuous chewing by a series of selective D-1 dopamine receptor agonists: Two directions of D-1:D-2 interaction. Eur. J. Pharmacol. 160:1989;377-384.
175. Murrin L.C. In vivo studies of dopamine receptor ontogeny. Life Sci. 31:1982;971-980.
176. Murrin L.C., Coyle J.T., Kuhar M.J. Striatal opiate receptors: Pre- and postsynaptic localization. Life Sci. 27:1980;1175-1183.
177. Murrin L.C., Ferrer J.R. Ontogeny of the rat striatum: Correspondence of dopamine terminals, opiate receptors and acetylcholinesterase. Neurosci. Lett. 47:1984;155-160.
178. Murrin L.C., Gibbons D.L., Ferrer J.R. Ontogeny of dopamine, serotonin and spirodecanone receptors in rat forebrain - An autoradiographic study. Dev. Brain Res. 23:1985;91-109.
179. Murrin L.C., Zeng W. Postnatal ontogeny of dopamine D2 receptors in rat striatum. Biochem. Pharmacol. 35:1986;1159-1162.
180. 1 receptor development in the rat striatum: Early localization in striosomes. Brain Res. 480:1989;170-177.
181. Neal B.S., Joyce J.N. Dopamine D1 receptor behavioral responsitivity following selective lesions of the striatal patch compartment during development. Dev. Brain Res. 60:1991;105-113.
182. 2 receptors. Synapse. 11:1992;35-46.
183. Neal-Beliveau B.S., Joyce J.N. D1 and D2 receptors do not up-regulate in response to neonatal intrastriatal 6-hydroxydopamine lesions. Neurosci. Lett. 160:1993;77-80.
184. Neal-Beliveau, B.S.; Joyce, J.N. Timing of the lesion is a critical determinant of the long-term effects of neonatal dopamine (DA) depletion in the rat. In preparation.
185. Neal-Beliveau, B.S.; Joyce, J.N.; Lucki, I. .SCH23390- and haloperidol-induced catalepsy: Effects of dopamine and serotonin receptor agonists. In preparation.
186. Neisewander J.L., Lucki I., McGonigle P. Behavioral and neurochemical effects of chronic administration of reserpine and SKF-38393 in rats. J. Pharmacol. Exp. Ther. 257:1991;850-860.
187. 3H-spiroperidol binding to rat forebrain sections: Plasticity of neostriatal dopamine receptors after nigro-striatal injury. Brain Res. 302:1984;9-18.
188. Neve K.A., Kozlowski M.R., Marshall J.F. Plasticity of neostriatal dopamine receptors after nigrostriatal injury: Relationship to recovery of sensorimotor functions and behavioral supersensitivity. Brain Res. 244:1982;33-44.
189. Newman-Gage H., Graybiel A.M. Expression of calcium/calmodulin-dependent protein kinase in relation to dopamine islands and synaptic maturation in the cat striatum. J. Neurosci. 8:1988;3360-3375.
190. Nisenbaum E.S., Stricker E.M., Zigmond M.J., Berger T.W. Long-term effects of dopamine-depleting brain lesions on spontaneous activity of type II striatal neurons: Relation to behavioral recovery. Brain Res. 398:1986;221-230.
191. Noison E., Thomas W.E. Ontogeny of dopaminergic function in the rat midbrain tegmentum, corpus striatum and frontal cortex. Dev. Brain Res. 41:1988;241-252.
192. 3H]spiperone binding: Regulation by sodium and guanine nucleotide in rats. J. Neurochem. 38:1982;902-908.
193. 1 binding sites in the striatum of the mutant Weaver mouse. Neuroscience. 28:1989;69-82.
194. Olson L., Seiger A., Fuxe K. Heterogeneity of striatal and limbic dopamine innervation: Highly fluorescent islands in developing and adult rats. Brain Res. 44:1972;283-288.
195. Onali P., Olianas M.C., Gessa G.L. Selective blockade of dopamine D-1 receptors by SCH 23390 discloses striatal dopamine D-2 receptors mediating the inhibition of adenylate cyclase in rats. Eur. J. Pharmacol. 99:1984;127-128.
196. Pappas B.A., Gallivan J.V., Dugas T., Saari M., Ings R. Intraventricular 6-hydroxydopamine in the newborn rat and locomotor responses to drugs in infancy: No support for the dopamine depletion model of minimal brain dysfunction. Psychopharmacology. 70:1980;41-46.
197. Pardo J.V., Creese I., Burt D.R., Snyder S.H. Ontogenesis of dopamine receptor binding in the corpus striatum of the rat. Brain Res. 125:1977;376-382.
198. Parenti M., Gentelman S., Olianas M.C., Neff N.H. The dopamine receptor adenylate cyclase complex: Evidence for post recognition site involvement for the development of supersensitivity. Neurochem. Res. 7:1982;115-124.
199. Pasinetti G.M., Lerner S.P., Johnson S.A., Morgan D.G., Telford N.A., Finch C.E. Chronic lesions differentially decrease tyrosine hydroxylase messenger RNA in dopaminergic neurons of the substantia nigra. Mol. Brain Res. 5:1989;203-209.
200. Pasinetti G.M., Osterburg H.H., Kelly A.B., Kohama S., Morgan D.G., Reinhard J.F. Jr., Stellwagen R.H., Finch C.E. Slow changes of tyrosine hydroxylase gene expression in dopaminergic brain neurons after neurotoxin lesioning: A model for neuron aging. Mol. Brain Res. 13:1992;63-73.
201. Paul M.L., Graybiel A.M., David J.-C., Robertson H.A. D1-like and D2-like dopamine receptors synergistically activate rotation and c-fos expression in the dopamine-depleted striatum in a rat model of Parkinson's disease. J. Neurosci. 12:1989;47-60.
202. Phelps P.E., Brady D.R., Vaughn J.E. The generation and differentiation of cholinergic neurons in rat caudate-putamen. Dev. Brain Res. 46:1989;47-60.
203. 2 dopamine receptors. Mol. Brain Res. 12:1992;111-119.
204. 2 dopaminergic regulation of striatal preproenkephalin mRNA levels is mediated at least in part through cholinergic interneurons. Mol. Brain Res. 13:1992;35-41.
205. Potter B.M., Bruno J.P. Food intake of rats depleted of dopamine as neonates is impaired by inhibition of catecholamine biosynthesis. Neurosci. Lett. 107:1989;295-300.
206. Pugh M.T., O'Boyle K.M., Molloy A.G., Waddington J.L. Effects of the putative D-1 antagonist SCH 23390 on stereotyped behavior induced by the D-2 agonist RU24213. Psychopharmacology. 87:1985;308-312.
207. 2 dopamine receptors. J. Neurochem. 62:1994;411-420.
208. 2 receptors in adult rat brain after neonatal destruction of nigrostriatal dopamine neurons: A quantitative autoradiographic study. Brain Res. 606:1993;273-285.
209. Radja F., El Mansari M., Soghomonian J.-J., Dewar K.M., Ferron A., Reader T.A., Descarries L. Changes of D1 and D2 receptors in adult rat neostriatum after neonatal dopamine denervation: Quantitative data from ligand binding, in situ hybridization and iontophoresis. Neuroscience. 57:1993;635-648.
210. Rao P.A., Molinoff P.B., Joyce J.N. Ontogeny of dopamine D1 and D2 receptor subtypes in rat basal ganglia: A quantitative autoradiographic study. Dev. Brain Res. 60:1991;167-177.
211. Reisert I., Schuster R., Zienecker R., Pilgrim C. Prenatal development of mesencephalic and diencephalic dopaminergic systems in the male and female rat. Dev. Brain Res. 53:1990;222-229.
212. Restani P., Corsini E., Galimberti R., Galli C.L. Postnatal ontogenesis of dopaminergic and serotonergic systems in rat caudate nucleus. Pharmacol. Res. 22:1990;343-350.
213. 3H]Hemicholinium-3 binding in rabbit striatum: Correspondence with patchy acetylcholinesterase staining and a method for quantifying striatal compartments. Brain Res. 412:1987;400-404.
214. Richfield E.K., Young A.B., Penney J.B. Comparative distribution of D-1 and D-2 receptors in the basal ganglia of turtles, pigeons, rats, cats, and monkeys. J. Comp. Neurol. 262:1987;446-463.
215. Robertson G.S., Robertson H.A. Synergistic effects of D1 and D2 dopamine agonists on turning behavior in rats. Brain Res. 384:1986;387-390.
216. Robinson T.E., Castañeda E., Whishaw I.Q. Compensatory changes in striatal dopamine neurons following recovery from injury induced by 6-OHDA or methamphetamine: A review of evidence from microdialysis studies. Can. J. Psych. 44:1990;253-275.
217. Rosengarten, H.; Friedhoff, A.J. Effect of prenatal neuroleptic treatment on membrane receptor development in the brain. In: Parvez, H.; Parvez, S., eds. Biogenic amines in development. Amsterdam: Elsevier; 1980:607-616.
218. Rosengarten H., Schweitzer J.W., Friedhoff A.J. Induction of oral dyskinesia in naive rats by D-1 stimulation. Life Sci. 33:1983;2479-2482.
219. Rosengarten H., Schweitzer J.W., Friedhoff A.J. Selective dopamine D-2 receptor reduction enhances a D-1 mediated oral dyskinesia in rats. Life Sci. 39:1986;29-35.
220. Savasta M., Dubois A., Benavides J., Scatton B. Different plasticity changes in D1 and D2 receptors in rat striatal subregions following impairment of dopaminergic transmission. Neurosci. Lett. 85:1988;119-124.
221. Savasta M., Dubois A., Feuerstein C., Manier M., Scatton B. Denervation supersensitivity of striatal D2 dopamine receptors is restricted to the ventro- and dorsolateral regions of the striatum. Neurosci. Lett. 74:1987;180-186.
222. 3H]SCH23390. Brain Res. 375:1986;291-301.
223. Savasta M., Ruberte E., Palacios J.M., Mengod G. The colocalization of cholecystokinin and tyrosine hydroxylase mRNAs in mesencephalic dopaminergic neurons in the rat brain examined by in situ hybridization. Neuroscience. 29:1989;363-369.
224. Scalzo F.M., Holson R.R., Gough B.J., Ali S.F. Neurochemical effects of prenatal haloperidol exposure. Pharmacol. Biochem. Behav. 34:1989;721-725.
225. Schallert T., Petrie B.F., Whishaw I.Q. Neonatal dopamine depletion: Spared and unspared sensorimotor and attentional disorders and effects of further depletion in adulthood. Psychobiology. 17:1989;386-396.
226. Shaywitz B.A., Teicher M.H., Cohen D.J., Anderson G.M., Young J.G. Dopaminergic but not adrenergic mediation of hyperactivity and performance deficits in developing rat pup. Psychopharmacology. 82:1984;73-77.
227. Shaywitz B.A., Yager R.D., Klopper J.H. Selective brain dopamine depletion in developing rats: An experimental model of minimal brain dysfunction. Science. 191:1976;305-308.
228. Sherman T.G., Moody C.A. Alterations in tyrosine hydroxylase expression following partial lesions of the nigrostriatal bundle. Mol. Brain Res. 29:1995;285-296.
229. Sivam S.P. D1 dopamine receptor-mediated substance P depletion in the striatonigral neurons of rats subjected to neonatal dopaminergic denervation: Implications for self-injurious behavior. Brain Res. 500:1989;119-130.
230. Sivam S.P., Breese G.R., Krause J.E., Napier T.C., Mueller R.A., Hong J.-S. Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression. J. Neurochem. 49:1987;1623-1633.
231. Smart, I.H.M.; Sturrock, R.R. Ontogeny of the neostriatum. In: Divac, I.; Oberg, R.G.E., eds. The neostriatum. New York: Pergamon Press; 1979:127-146.
232. Smith R.D., Cooper B.R., Breese G.R. Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: Evidence for involvement of brain dopamine. J. Pharmacol. Exp. Ther. 185:1973;609-619.
233. Snyder A.M., Stricker E.M., Zigmond M.J. Stress-induced neurological impairments in an animal model of parkinsonism. Ann. Neurol. 18:1985;544-554.
234. Snyder A.M., Zigmond M.J., Lund R.D. Sprouting of serotonergic afferents into striatum after dopamine-depleting lesions in infant rats: A retrograde transport and immunocytochemical study. J. Comp. Neurol. 245:1986;274-281.
235. Snyder-Keller A.M. Development of striatal compartmentalization following pre- and postnatal dopamine depletion. J. Neurosci. 11:1991;810-821.
236. Snyder-Keller A.M., Carder R.K., Lund R.D. Development of dopamine innervation and turning behavior in dopamine-depleted infant rats receiving unilateral nigral transplants. Neuroscience. 30:1989;779-794.
237. Soghomonian J.-J. Effects of neonatal 6-hydroxydopamine injections on glutamate decarboxylase, preproenkephalin and dopamine D2 receptor mRNAs in the adult rat striatum. Brain Res. 621:1993;249-259.
238. Soghomonian J.-J., Gonzales C., Chesselet M.-F. Messenger RNAs encoding glutamate decarboxylases are differentially affected by nigrostriatal lesions in subpopulations of striatal neurons. Brain Res. 567:1992;68-79.
239. Sokoloff P., Giros B., Martres M.-P., Bouthenet M.-L., Schwartz J.-C. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 347:1990;146-151.
240. Solberg Y., Pollack Y., Silverman W.F. Differential expression of tyrosine hydroxylase mRNA in the developing rat mesencephalon. Cell. Mol. Neurobiol. 12:1992;569-580.
241. Sonsalla P.K., Manzino L., Heikkila R.E. Interactions of D1 and D2 dopamine receptors on the ipsilateral vs. contralateral side in rats with unilateral lesions of the dopaminergic nigrostriatal pathway. J. Pharmacol. Exp. Ther. 247:1988;180-185.
242. Specht L.A., Pickel V.M., Joh T.H., Reis D.J. Light microscopic immunocytochemical localization of tyrosine hydroxylase in prenatal rat brain. I. Early ontogeny. J. Comp. Neurol. 199:1981;233-253.
243. Specht L.A., Pickel V.M., Joh T.H., Reis D.J. Light microscopic immunocytochemical localization of tyrosine hydroxylase in prenatal rat brain. II. Late ontogeny. J. Comp. Neurol. 199:1981;233-253.
244. Spirduso W.W., Gilliam P.E., Schallert T., Upchurch M., Vaughn D.M., Wilcox R.E. Reactive capacity: A sensitive behavioral marker of movement initiation and nigrostriatal dopamine function. Brain Res. 335:1985;255-276.
245. 2 receptor mRNA in rat brain. Eur. J. Pharmacol. 225:1992;143-150.
246. Stachowiak M.K., Bruno J.P., Snyder A.M., Stricker E.M., Zigmond M.J. Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Res. 291:1984;164-167.
247. Stachowiak M.K., Keller R.W., Stricker E.M., Zigmond M.J. Increased dopamine efflux from striatal slices during development and after nigrostriatal bundle damage. J. Neurosci. 7:1987;1648-1654.
248. Starr B.S., Starr M.S. Differential effects of dopamine D1 and D2 agonists and antagonists on the velocity of movement, rearing and grooming in the mouse. Neuropharmacology. 25:1986;455-463.
249. Steindler D.A., O'Brien O., Cooper N.G.F. Glycoconjugate boundaries during early postnatal development of the neostriatal mosaic. J. Comp. Neurol. 267:1988;357-369.
250. Stellar J.R., Waraczynski M., Bruno J.P. Neonatal dopamine depletions spare lateral hypothalamic stimulation reward in adult rats. Pharmacol. Biochem. Behav. 30:1988;365-370.
251. Stoof J.C., Kebabian J.W. Opposing roles for D-1 and D-2 dopamine receptors in efflux of cyclic AMP from rat striatum. Nature. 294:1981;366-368.
252. Stricker, E.M.; Zigmond, M.J. Recovery of function following damage to central catecholaminergic neurons: A neurochemical model for the lateral hypothalamic syndrome. In: Sprague, J. M.; Epstein, A. N., eds. Progress in psychobiology and physiological psychology. New York: Academic Press; 1976:121-189.
253. Takeichi T., Kurumiya S., Umemoto M., Olds M.E. Roles of catecholamine terminals and intrinsic neurons of the ventral regmentum in self-stimulation investigated in neonatally dopamine-depleted rats. Pharmacol. Biochem. Behav. 24:1986;1101-1109.
254. 3H]dopamine uptake. Brain Res. 46:1972;251-285.
255. Tennyson V.M., Budininkas-Schoenenbeck M., Gershon P. Effects of chronic reserpine treatment on development of maturity of the putamen in fetal rabbit. Brain Res. Bull. 9:1982;651-662.
256. Towle A.C., Criswell H.E., Maynard E.H., Lauder J.M., Loh T.H., Mueller R.A., Breese G. Serotonergic innervation of the rat caudate following a neonatal 6-hydroxydopamine lesion: An anatomical, biochemical and pharmacological study. Pharmacol. Biochem. Behav. 34:1989;367-374.
257. Ungerstedt U. Adipsia and aphagia after 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine system. Acta Physiol. Scand. Suppl. 367:1971;95-122.
258. van der Kooy D. Developmental relationships between opiate receptors and dopamine in the formation of caudate/putamen patches. Dev. Brain Res. 14:1984;300-303.
259. van der Kooy D., Fishell G. Neuronal birthdate underlies the development of striatal compartments. Brain Res. 401:1987;155-161.
260. van der Kooy D., Fishell G. Embryonic lesions of the substantia nigra prevent the patchy expression of opiate receptors, but not the segregation of patch and matrix compartment neurons, in the developing striatum. Dev. Brain Res. 66:1992;141-145.
261. Voorn P., Kalsbeek A., Jorritsma-Byham Bl., Groenewegen H.J. The pre- and postnatal development of the dopaminergic cell groups in the ventral mesencephalon and the dopaminergic innervation of the striatum of the rat. Neuroscience. 25:1988;857-887.
262. Voorn P., Roest G., Groenewegen H.J. Increase of enkephalin and decrease of substance P immunoreactivity in the dorsal and ventral striatum of the rat after midbrain 6-hydroxydopamine lesions. Brain Res. 412:1987;391-396.
263. Waddington J.L., O'Boyle K.M. The D-1 dopamine receptor and the search for its functional role: From neurochemistry to behavior. Rev. Neurosci. 1:1987;157-184.
264. Waddington J.L., O'Boyle K.M. Drugs acting on brain dopamine receptors: A conceptual re-evaluation five years after the first selective D-1 antagonist. Pharmacol. Ther. 34:1989;1-52.
265. Walker P.D., Riley L.A., Hart R.P., Jonakai G.M. Serotonin regulation of neostriatal tachykinins following neonatal 6-hydroxydopamine lesions. Brain Res. 557:1991;31-36.
266. Walters J.R., Bergstrom D.A., Carlson J.H., Chase T.N., Braun A.R. D1 dopamine receptor activation required for postsynaptic expression of D2 agonist effects. Science. 236:1987;719-722.
267. Weick B.G., Walters J.R. D1 dopamine receptor stimulation potentiates neurophysiological effects of bromocriptine in rats with lesions of the nigrostriatal dopamine pathway. Neuropharmacology. 26:1987;641-644.
268. Weick B.G., Walters J.R. Effects of D1 and D2 dopmine receptor stimulation on the activity of substantia nigra pars reticulata neurons in 6-hydroxydopamine lesioned rats: D1/D2 coactivation induces potentiated responses. Brain Res. 523:1990;16-22.
269. Weihmuller F.B., Bruno J.P. Age-dependent plasticity in the dopaminergic control of sensorimotor development. Behav. Brain Res. 35:1989;95-109.
270. Weihmuller F.B., Bruno J.P. Drinking behavior and motor function in rat pups depleted of brain dopamine during development. Dev. Psychobiol. 22:1989;101-114.
271. Whishaw I.Q., Funk D.R., Haeryluk S.J., Karbashewski E.D. Absence of sparing of spatial navigation, skilled forelimb and tongue use and limb posture in the rat after neonatal dopamine depletion. Physiol. Behav. 40:1987;247-253.
272. Whishaw I.Q., Gorny B., Tran-Nguyen L.T.L., Castañeda E., Miklyaeva E.I., Pellis S.M. Making two movements at once: Impairments of movement, posture, and their integration underlie the adult skilled reaching deficit of neonatally dopamine-depleted rats. Behav. Brain Rev. 61:1994;63-77.
273. White F.J., Bednarz L.M., Wachtel S.R., Hjorth S., Brooderson R.J. Is stimulation of both D1 and D2 receptors necessary for the expression of dopamine-mediated behaviors? Pharmacol. Biochem. Behav. 30:1988;189-193.
274. 2 dopamine receptor interactions. London: Academic Press; 1993:79-114.
275. Wright A.K., Arbuthnott G.W. The pattern of innervation of the corpus striatum by the substantia nigra. Neuroscience. 6:1981;2063-2067.
276. 2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment. Life Sci. 50:1992;383-396.
277. Young W.S., Bonner T.I., Brann M.R. Mesencephalic dopamine neurons regulate the expression of neuropeptide mRNAs in the rat forebrain. Proc. Natl Acad. Sci. USA. 83:1986;9827-9831.
278. Zahm D.S., Eggerman K.W., Sprung R.F., Wesche D.E., Payne E. Postnatal development of striatal neurotensin immunoreactivity in relation to clusters of substance P immunoreactive neurons and the "dopamine islands" in the rat. J. Comp. Neurol. 296:1990;403-414.
279. Zeng W., Hyttel J., Murrin L.C. Ontogeny of dopamine D1 receptors in rat striatum. J. Neurochem. 50:1988;862-867.
280. Zigmond M.J., Acheson A.L., Stachowiak M.K., Stricker E.M. Neurochemical compensation after nigrostriatal bundle injury in an animal model of preclinical parkinsonism. Arch. Neurol. 41:1984;856-861.
281. Zigmond M.J., Stricker E.M. Recovery of feeding and drinking by rats after intraventricular 6-hydroxydopamine or lateral hypothalamic lesions. Science. 182:1973;717-720.
282. Zigmond M.J., Stricker E.M. Parkinson's disease: Studies with an animal model. Life Sci. 35:1984;5-18.
283. Zigmond, M.J.; Stricker, E.M. Adaptive properties of monoaminergic neurons and their functional implications. In: Lajtha, A., ed. Handbook of Neurochemistry, vol. 9. New York: Plenum Press; 1985:87-102.
284. Zigmond M.J., Stricker E.M. Animal models of parkinsonism using selective neurotoxins: Clinical and basic implications. Int. Rev. Neurobiol. 31:1989;1-79.
285. Zigmond, M.J.; Stricker, E.M.; Berger, T.W. Parkinsonism: Insights from animal models utilizing neurotoxic agents. In: Coyle, J. T., ed. Experimental models of dementing disorders: A synaptic neurochemical perspective. New York: Liss; 1987:1-38.